Janux Therapeutics, Inc. (JANX)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3) — the strategy requires fundamentalScore ≥ 3 before any bullish entry; independently, the chart offers no qualifying long setup (price 11.37 at a 52-week low below SMA20/50/200 with MACD -1.34 below signal and widening negative).
Company overview
Janux Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapies using its TRACTr platform to activate T cells against tumors. The company is advancing several early-stage TRACTr product candidates targeting specific antigens and is also developing a TRACIr immunomodulator to enhance T cell activity. Founded in 2017, Janux is headquartered in La Jolla, California.
Fundamental
weakJanux's strong cash position contrasts with speculative fundamentals and binary clinical risks.
Cash-rich, loss-making clinical-stage biotech: roughly $945.7 million of cash and investments with no debt and no going-concern issues, but no product revenue, a ~$99.8 million trailing net loss, negative free cash flow, a discontinued program (JANX008) and the lead asset's next clinical data not expected until the first half of 2027. Trading below cash, but binary clinical risk, dilution overhang and a catalyst vacuum keep the fundamental picture speculative rather than investment-worthy.
Sentiment
fairSentiment is mixed, with a recent earnings beat partially offset by a downgrade.
The dominant catalyst is the 2026-11-05 Q3 2026 earnings print (announced): revenue of $9.3M beat the $8.0M FactSet estimate, the loss came in narrower than consensus, and the tape rewarded it with a ~9.8% one-day gain — but the Wolfe Research downgrade to Peer Perform (2026-11-12, announced) plus renewed valuation pushback leave the signal genuinely two-sided, with the measured media delta improving determinate from a +0.089 baseline to +0.32 in the 14-day window. Red-Flag Screen: no severe flag fired, the moderate conflicting-catalysts flag fired because a bullish and a bearish catalyst both sit inside the actionable window on a complete array, so the moderate red-flag cap applies at a ceiling of 3; the legal screen is clean and retail is unmeasured (Reddit access blocked).
Technical
very weakThe stock is in a confirmed downtrend, trading at a 52-week low with no bullish setup.
Broken structure, not a bullish setup: JANX closed 11.37 on 2026-11-13 at a fresh 52-week low, below SMA20 (15.95), SMA50 (16.80), SMA200 (15.36) and the entire EMA/WMA/DEMA/TEMA stack, after a 2026-11-09 range-expansion session (-28.9%, range 5.52 ≈ 4.7x ATR14). MACD line -1.34 sits below its -0.65 signal with a widening negative histogram, and ADX 24.38 is rising while price is below all averages — a strong downtrend, not an oversold reversal. RSI 28.92 and Williams %R -97.18 are deeply oversold but only support a reflex bounce, not a 1-15 day long. technicalScore 1; the trade is additionally hard-blocked by fundamentalScore 2 < 3.
You’re looking at 2026-11-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

